Stempoint Capital’s Pyxis Oncology PYXS Stock Holding History

Stempoint Capital’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-689,538	Closed	-$1.53M	–	106
2025 Q3	$1.53M	Buy	+689,538	New	+$993K	0.31%	58
2024 Q4	–	Sell	-850,210	Closed	-$3.12M	–	72
2024 Q3	$3.12M	Sell	850,210 -352,465	-29%	-$1.23M	0.93%	29
2024 Q2	$3.98M	Sell	1,202,675 -591,520	-33%	-$2.49M	1.17%	28
2024 Q1	$7.64M	Buy	+1,794,195	New	+$7.55M	2.02%	16

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stempoint Capital's PYXS Position: Q4 2025 in Review

Stempoint Capital sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 689,538 shares — an estimated $1.53M sold.

Stempoint Capital first reported a position in PYXS in Q1 2024 and held it in 4 quarters. The position peaked at $7.64M in Q1 2024. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

Stempoint Capital reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
Stempoint Capital sold 689,538 Pyxis Oncology shares in Q4 2025, an estimated $1.53M.
Stempoint Capital first reported a position in Pyxis Oncology in Q1 2024 and held it in 4 quarters.
Stempoint Capital's Pyxis Oncology position peaked at $7.64M in Q1 2024.
79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.